Imugene Ltd IMU

Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) is raising about A$11.12 million before costs through a two-tranche placement, strengthening its balance sheet as it advances its lead cell therapy asset azer-cel through key clinical and regulatory milestones. The placement follows positive early...

Imugene Ltd (ASX:IMU, OTC:IUGNF) earlier this week reported a second complete response in the concurrent Bruton Tyrosine Kinase inhibitor, or BTKi, cohort of its ongoing Phase 1b azer-cel trial, adding momentum to an early clinical signal in patients with limited remaining treatment...

Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) earlier this week reported the first complete response in the concurrent Bruton Tyrosine Kinase inhibitor, or BTKi, cohort of its ongoing Phase 1b azer-cel trial, marking an early clinical signal in a patient population with limited remaining treatment...

Imugene Ltd MD and CEO Leslie Chong talked with Proactive about the company reporting a second complete response in the concurrent Bruton Tyrosine Kinase inhibitor, or BTKi, cohort of its ongoing Phase 1b azer-cel trial. The latest response was recorded in the first mantle cell lymphoma, or MCL, patient treated in the azer-cel Phase 1b study. The patient had previously received and failed BTKi therapy before achieving a complete response at the Day 28 assessment. The result follows closely after Imugene Ltd reported its first complete response in the concurrent BTKi cohort, highlighting a seco

Just a day after reporting the first complete response in the concurrent Bruton Tyrosine Kinase inhibitor (BTKi) cohort of its ongoing Phase 1b azer-cel trial, Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) has reported a second complete response, adding momentum to an early clinical signal in...

Imugene Ltd managing director and CEO Leslie Chong talked with Proactive about the first complete response reported in the concurrent Bruton Tyrosine Kinase inhibitor, or BTKi, cohort of the company’s ongoing Phase 1b azer-cel trial. Chong said the result was an important milestone for patients with limited remaining treatment options, particularly those who had relapsed on or become refractory to BTKi therapy. The first patient in the cohort, who had follicular lymphoma and had previously failed BTKi therapy, achieved a complete response at the Day 28 assessment. Chong explained that a comple

Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) has reported the first complete response in the concurrent Bruton Tyrosine Kinase inhibitor (BTKi) cohort of its ongoing Phase 1b azer-cel trial, marking an early clinical signal in a patient group with limited remaining treatment options. The first...

Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) earlier this week announced that the US Food and Drug Administration (FDA) granted Fast Track Designation to its allogeneic CAR T therapy azer-cel for relapsed or refractory chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) and relapsed...

The S&P/ASX Small Ordinaries Index continued its strong run, climbing 2.28% on Friday to close at 3,501.80 and gaining 2.19% over the past five trading days, reflecting renewed investor appetite for growth-oriented small-cap stocks. This morning, several ASX-listed companies have...

Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) recently highlighted encouraging new clinical data for its allogeneic CAR-T therapy Azer-Cel, while also confirming the company will present the program at the upcoming American Society of Clinical Oncology (ASCO) conference. Managing director Dr...

Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) has dosed the first patient in the Bruton Tyrosine Kinase inhibitor (BTKi) combination cohort of its Phase 1b azer-cel study, marking a key expansion of the company’s clinical program into a global market valued at about US$12 billion in 2025. The...

Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) has appointed Dr Charmaine Gittleson and Michael Kotsanis as non-executive directors as part of a board enhancement process aimed at supporting the company’s clinical-stage cell therapy strategy. Both appointments take effect from June 30,...

Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) has reported encouraging early response rates from the CAR T-naïve cohort of its ongoing Phase 1b azer-cel trial ahead of a major presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The clinical-stage...

New York, May 20, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research, an equity research firm with a focus on small capitalization public companies has released an update note on Imugene Ltd. (ASX: IMU) resuming coverage. The research summary below is from a report commissioned by Imugene Ltd. and produced by Diamond Equity Research. The in-depth 24-page update note includes detailed information on the Imugene’s business model, industry, financial results, and risks. The full research report is av

Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) could be significantly undervalued as its focused push into allogeneic CAR-T therapy gathers momentum, according to a new initiation report from RaaS Research, which has assigned the company a risk-adjusted valuation of $0.24 per share — representing...

Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) has highlighted encouraging early clinical data and fresh funding in its March 2026 quarterly report, as the company sharpens its focus on its lead CAR T therapy, azer-cel. The clinical-stage immuno-oncology company highlighted positive results from...